Breakthroughs in Epstein-Barr Virus and Follicular Lymphoma Research Offer Hope

Seattle, WA – March 4, 2026 – Recent advances from Fred Hutch Cancer Center are offering new avenues for combating both the widespread Epstein-Barr virus (EBV) and the historically difficult-to-treat follicular lymphoma. Researchers have developed a novel antibody showing promise in blocking EBV infection, while a long-term analysis suggests a significant cure rate for follicular lymphoma patients receiving a specific treatment regimen. Simultaneously, a statewide plan is underway in Washington to reduce cancer rates and improve equity in cancer care.

Blocking a Ubiquitous Virus: A New Antibody Against Epstein-Barr

Scientists at Fred Hutch have achieved a milestone in the fight against Epstein-Barr virus, a pathogen that infects an estimated 95% of the global population and is linked to a range of health issues, including certain cancers and neurodegenerative diseases. The research, published in Cell Reports Medicine, details the development of a genetically human monoclonal antibody capable of preventing EBV from infecting human immune cells. This is particularly significant given that EBV uniquely targets nearly all B cells, making it a challenging virus to block.

The team, led by Andrew McGuire, PhD, a biochemist and cellular biologist in the Vaccine and Infectious Disease Division at Fred Hutch, focused on two key antigens on the virus surface: gp350, which facilitates binding to cells and gp42, which enables viral entry through a process called fusion. Using a mouse model engineered with human antibody genes, researchers identified antibodies against both antigens, with one monoclonal antibody successfully blocking infection in mice with human immune systems. Dr. McGuire explained that finding human antibodies that effectively block EBV without triggering an immune response against the antibody itself was a major hurdle. This new approach appears to overcome that challenge.

The development of these antibodies represents a critical step toward potentially blocking one of the world’s most common viruses. Currently, McGuire and Crystal Chhan are working to advance a potential therapy specifically for immunocompromised patients, who are particularly vulnerable to EBV-related complications.

Follicular Lymphoma: A Potential for Cure

For years, follicular lymphoma (FL) has been considered largely incurable. However, new long-term data published in JAMA Oncology is challenging that perception. Research led by Mazyar Shadman, MD, MPH, examined 15 years of follow-up data from patients with FL who received a chemoimmunotherapy regimen. The findings reveal a cure rate of 42% – a remarkable result for a cancer previously thought to be managed, rather than cured.

This discovery has the potential to significantly impact how clinicians discuss treatment options and follow-up care with their patients. While further research is needed to understand the factors contributing to these successful outcomes, the data offers a renewed sense of hope for individuals diagnosed with follicular lymphoma.

Washington State’s Cancer Action Plan

Beyond these specific research breakthroughs, Washington state is taking a proactive approach to cancer prevention and control with the launch of the Cancer Action Plan of Washington (CAPOW). This five-year strategic plan aims to reduce cancer rates and deaths statewide by focusing on key areas such as health literacy, cancer screening, prevention efforts, and addressing health inequities.

CAPOW is a collaborative effort, bringing together healthcare facilities, Native and tribal leaders, academic research institutions, and cancer care organizations. The plan aligns with both federal and state goals, demonstrating a unified commitment to improving cancer outcomes for all Washington residents.

Other Notable Research from Fred Hutch

Fred Hutch researchers are likewise making strides in other areas of cancer research. A recent study in Nature Genetics, led by Haolong Li, PhD, developed a method for monitoring androgen receptor (AR) levels within prostate cancer cells. This technique could reveal new therapeutic vulnerabilities and provide a better understanding of hormone-driven cancers. Researchers are investigating the importance of blood donations, particularly given ongoing shortages, and emphasizing that supplements offer little benefit in cancer prevention, with some potentially increasing risk.

The Importance of Blood Donation and Supplement Awareness

With ongoing blood supply shortages, Fred Hutch’s Medical Director of Transfusion, Sandhya Panch, MD, MPH, is urging people to donate blood, highlighting the critical impact it has on cancer patients. Simultaneously, researchers like Garnet Anderson, PhD, Heather Greenlee, ND, PhD, MPH, and Suz Stein, MDM, RD, are cautioning against the widespread use of dietary supplements, noting that they offer minimal benefit and can even be detrimental to health.

Looking Ahead: Continued Research and Improved Outcomes

The advancements announced by Fred Hutch represent a significant step forward in the fight against EBV, follicular lymphoma, and cancer overall. Ongoing research, coupled with statewide initiatives like CAPOW, promises to further improve cancer prevention, treatment, and outcomes for patients in Washington state and beyond. The focus now shifts to translating these research findings into tangible benefits for patients, including the development of new therapies and improved screening strategies. Further studies will be crucial to refine treatment protocols and identify individuals most likely to benefit from these advancements.